<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01132547</url>
  </required_header>
  <id_info>
    <org_study_id>SCUSF 0703</org_study_id>
    <secondary_id>SCUSF-0703</secondary_id>
    <secondary_id>5U10CA081920-11</secondary_id>
    <nct_id>NCT01132547</nct_id>
  </id_info>
  <brief_title>Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer</brief_title>
  <official_title>Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of South Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Cyproheptadine hydrochloride may prevent weight loss caused by cancer or cancer
      treatment. It is not yet known whether cyproheptadine is more effective than a placebo in
      preventing weight loss in young patients receiving chemotherapy for cancer.

      PURPOSE: This randomized phase III trial is studying cyproheptadine hydrochloride to see how
      well it works in preventing weight loss in young patients receiving chemotherapy for cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine the effect of cyproheptadine hydrochloride in the prevention of cancer- or
           treatment-related weight loss (defined as ≥ 5% reduction in weight from baseline
           measurement) in children who are initiating a course of moderately or highly emetic
           chemotherapy.

      Secondary

        -  To investigate the effect of cyproheptadine HCl on the change in weight for age scores
           after 8 weeks of study drug administration in comparison to placebo.

        -  Investigate the relationship between the secondary outcome variables (prealbumin,
           triceps skin fold, mid-upper arm circumference, and weight loss)from baseline to end of
           treatment in each group (treatment and placebo) separately.

      OUTLINE: This is a multicenter study. Patients are stratified according to enrolling center
      and steroid use with cancer treatment (yes vs no). Study agent can start anytime up to and
      including day 28 after the first dose of chemotherapy.

        -  Arm I: Patients receive oral cyproheptadine hydrochloride twice daily for 8 weeks.

        -  Arm II: Patients receive an oral placebo twice daily for 8 weeks.

      Patients undergo weight and height measurements at baseline and at each follow-up visit in
      weeks 4 and 8 to evaluate the effect of cyproheptadine hydrochloride and duration of
      response. Patients or parents complete medicine logs at each follow-up visit in weeks 4 and 8
      to evaluate drug compliance and tolerance. Patients also undergo measures of nutrition; and
      measures of body composition, lean body mass, and fat percentage using standardized equipment
      and procedures for measuring triceps skin fold and mid-arm muscle circumference at baseline
      and at the end of the study.

      Patients undergo blood sample collection at baseline and at the end of the study for
      biomarker studies. Samples are analyzed for pre-albumin levels.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated due to slow accrual.
  </why_stopped>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participant With Weight Loss ≥ 5% at the 8- Week Assessment When Compared to Baseline</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of Weight Loss</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Change from Baseline in Weight Z score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pattern of Weight in the Study Population</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Change from Baseline in Weight</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I cyproheptadine hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral cyproheptadine hydrochloride twice daily for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive an oral placebo twice daily for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyproheptadine hydrochloride</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I cyproheptadine hydrochloride</arm_group_label>
    <other_name>cyproheptadine HCl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm II placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  ≥ 2 years and ≤ 21 years of age at the time of study entry

          -  Scheduled to receive chemotherapy for:

          -  Newly diagnosed:

          -  Non-rhabdo soft tissue sarcomas, scheduled to receive chemotherapy, as well as
             intermediate or high-risk rhabdomyosarcoma, any stage osteosarcoma and any stage
             Ewing's sarcoma

          -  Intermediate or high-risk neuroblastoma

          -  Wilms' tumor (Stage III/IV)

          -  Hepatoblastoma (Stage III/IV)

          -  Germ cell tumors (Stage III/IV)

          -  Brain tumors, including medulloblastoma, PNET and ependymomas

          -  AML

          -  Relapsed/recurrent disease (any patient)

          -  Able to register and randomize within 28 days of starting chemotherapy (registration
             /randomization and start of study agent may occur at anytime up to and including Day
             28 after the initiation of chemotherapy)

        EXCLUSION CRITERIA:

          -  ≥ 29 days after starting chemotherapy

          -  Documented history of unintended weight loss ≥ 5% presumed secondary to cancer within
             3 months of study entry

          -  Currently taking cyproheptadine HCl (or have taken cyproheptadine HCl within 3 weeks
             of study registration)

          -  History of anorexia nervosa or bulimia

          -  Taking other appetite-stimulating medications, i.e. dronabinol (Marinol) during the
             past three weeks.

          -  Initiation of other appetite enhancing agents, including steroids prescribed for the
             intent of weight gain, i.e. Megace. Note: Other forms of nutrition therapies, e.g.
             appetite-stimulating medications, TPN or enteral tube feedings are not allowed during
             this study.

          -  Children receiving steroids for &gt;7 days as part of their cancer treatment regimen are
             excluded from participation. However, intermittent steroid use in an antiemetic
             regimen is allowed during the study

          -  Receiving monoamine oxidase (MAO) inhibitors, procarbazine, fluoxetine (Prozac), or
             paroxetine (Paxil)

          -  Diagnosed with glaucoma, cystic fibrosis, inflammatory bowel disease, or GI/GU
             obstruction

          -  Allergy to cyproheptadine HCl

          -  Females of childbearing age must not be pregnant.

          -  Female patients who are lactating must agree to stop breast-feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey P. Krischer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Miller Children's Hospital</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Medical Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.I. duPont Hospital for Children</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Southwest Florida at Lee Memorial</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207-8482</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arnold Palmer Hospital for Children</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic - Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Hospital Pensacola</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kapiolani Medical Center for Women and Children</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96826</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRISTUS Santa Rosa Children's Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of The King's Daughters</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2010</study_first_submitted>
  <study_first_submitted_qc>May 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2010</study_first_posted>
  <results_first_submitted>January 12, 2015</results_first_submitted>
  <results_first_submitted_qc>June 4, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 2, 2015</results_first_posted>
  <last_update_submitted>June 4, 2015</last_update_submitted>
  <last_update_submitted_qc>June 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cachexia</keyword>
  <keyword>weight changes</keyword>
  <keyword>nausea and vomiting</keyword>
  <keyword>alveolar childhood rhabdomyosarcoma</keyword>
  <keyword>anaplastic osteosarcoma</keyword>
  <keyword>childhood alveolar soft-part sarcoma</keyword>
  <keyword>childhood angiosarcoma</keyword>
  <keyword>childhood epithelioid sarcoma</keyword>
  <keyword>childhood fibrosarcoma</keyword>
  <keyword>childhood gliosarcoma</keyword>
  <keyword>childhood leiomyosarcoma</keyword>
  <keyword>childhood liposarcoma</keyword>
  <keyword>childhood neurofibrosarcoma</keyword>
  <keyword>childhood synovial sarcoma</keyword>
  <keyword>chondrosarcoma</keyword>
  <keyword>chondrosarcomatous osteosarcoma</keyword>
  <keyword>clear cell sarcoma of the kidney</keyword>
  <keyword>embryonal childhood rhabdomyosarcoma</keyword>
  <keyword>embryonal-botryoid childhood rhabdomyosarcoma</keyword>
  <keyword>endometrial stromal sarcoma</keyword>
  <keyword>extraosseous Ewing sarcoma</keyword>
  <keyword>peripheral primitive neuroectodermal tumor</keyword>
  <keyword>fibrosarcomatous osteosarcoma</keyword>
  <keyword>localized Ewing sarcoma</keyword>
  <keyword>localized osteosarcoma</keyword>
  <keyword>mast cell sarcoma</keyword>
  <keyword>metastatic childhood soft tissue sarcoma</keyword>
  <keyword>metastatic Ewing sarcoma</keyword>
  <keyword>metastatic osteosarcoma</keyword>
  <keyword>mixed childhood rhabdomyosarcoma</keyword>
  <keyword>mixed osteosarcoma</keyword>
  <keyword>nonmetastatic childhood soft tissue sarcoma</keyword>
  <keyword>osteoblastic osteosarcoma</keyword>
  <keyword>ovarian carcinosarcoma</keyword>
  <keyword>ovarian sarcoma</keyword>
  <keyword>pleomorphic childhood rhabdomyosarcoma</keyword>
  <keyword>previously treated childhood rhabdomyosarcoma</keyword>
  <keyword>previously untreated childhood rhabdomyosarcoma</keyword>
  <keyword>recurrent adult soft tissue sarcoma</keyword>
  <keyword>recurrent childhood gliosarcoma</keyword>
  <keyword>recurrent childhood rhabdomyosarcoma</keyword>
  <keyword>recurrent childhood soft tissue sarcoma</keyword>
  <keyword>recurrent Ewing sarcoma</keyword>
  <keyword>recurrent osteosarcoma</keyword>
  <keyword>recurrent uterine sarcoma</keyword>
  <keyword>small intestine leiomyosarcoma</keyword>
  <keyword>stage I uterine sarcoma</keyword>
  <keyword>stage II uterine sarcoma</keyword>
  <keyword>stage III uterine sarcoma</keyword>
  <keyword>stage IV uterine sarcoma</keyword>
  <keyword>telangiectatic osteosarcoma</keyword>
  <keyword>untreated childhood gliosarcoma</keyword>
  <keyword>uterine carcinosarcoma</keyword>
  <keyword>uterine leiomyosarcoma</keyword>
  <keyword>localized resectable neuroblastoma</keyword>
  <keyword>localized unresectable neuroblastoma</keyword>
  <keyword>recurrent neuroblastoma</keyword>
  <keyword>regional neuroblastoma</keyword>
  <keyword>stage 4S neuroblastoma</keyword>
  <keyword>recurrent Wilms tumor</keyword>
  <keyword>childhood kidney tumors</keyword>
  <keyword>stage III Wilms tumor</keyword>
  <keyword>stage IV Wilms tumor</keyword>
  <keyword>childhood hepatoblastoma</keyword>
  <keyword>childhood extracranial germ cell tumor</keyword>
  <keyword>childhood extragonadal germ cell tumor</keyword>
  <keyword>childhood gonadal germ cell tumor</keyword>
  <keyword>childhood malignant ovarian germ cell tumor</keyword>
  <keyword>childhood malignant testicular germ cell tumor</keyword>
  <keyword>recurrent childhood malignant germ cell tumor</keyword>
  <keyword>recurrent extragonadal germ cell tumor</keyword>
  <keyword>recurrent extragonadal non-seminomatous germ cell tumor</keyword>
  <keyword>recurrent malignant testicular germ cell tumor</keyword>
  <keyword>recurrent ovarian germ cell tumor</keyword>
  <keyword>stage III extragonadal non-seminomatous germ cell tumor</keyword>
  <keyword>stage III malignant testicular germ cell tumor</keyword>
  <keyword>stage IIIA ovarian germ cell tumor</keyword>
  <keyword>stage IIIB ovarian germ cell tumor</keyword>
  <keyword>stage IIIC ovarian germ cell tumor</keyword>
  <keyword>stage IV extragonadal non-seminomatous germ cell tumor</keyword>
  <keyword>stage IV ovarian germ cell tumor</keyword>
  <keyword>recurrent childhood medulloblastoma</keyword>
  <keyword>untreated childhood medulloblastoma</keyword>
  <keyword>childhood ependymoblastoma</keyword>
  <keyword>childhood infratentorial ependymoma</keyword>
  <keyword>newly diagnosed childhood ependymoma</keyword>
  <keyword>recurrent childhood ependymoma</keyword>
  <keyword>recurrent childhood subependymal giant cell astrocytoma</keyword>
  <keyword>untreated childhood subependymal giant cell astrocytoma</keyword>
  <keyword>peripheral primitive neuroectodermal tumor of the kidney</keyword>
  <keyword>childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>recurrent childhood brain stem glioma</keyword>
  <keyword>recurrent childhood brain tumor</keyword>
  <keyword>untreated childhood brain stem glioma</keyword>
  <keyword>recurrent childhood anaplastic astrocytoma</keyword>
  <keyword>recurrent childhood anaplastic oligoastrocytoma</keyword>
  <keyword>recurrent childhood anaplastic oligodendroglioma</keyword>
  <keyword>stage I childhood anaplastic large cell lymphoma</keyword>
  <keyword>stage II childhood anaplastic large cell lymphoma</keyword>
  <keyword>stage III childhood anaplastic large cell lymphoma</keyword>
  <keyword>stage IV childhood anaplastic large cell lymphoma</keyword>
  <keyword>untreated childhood anaplastic astrocytoma</keyword>
  <keyword>untreated childhood anaplastic oligoastrocytoma</keyword>
  <keyword>untreated childhood anaplastic oligodendroglioma</keyword>
  <keyword>childhood high-grade cerebellar astrocytoma</keyword>
  <keyword>childhood low-grade cerebellar astrocytoma</keyword>
  <keyword>recurrent childhood astrocytoma</keyword>
  <keyword>other tumor of glial origin</keyword>
  <keyword>recurrent childhood cerebellar astrocytoma</keyword>
  <keyword>recurrent childhood cerebral astrocytoma</keyword>
  <keyword>recurrent childhood diffuse astrocytoma</keyword>
  <keyword>recurrent childhood fibrillary astrocytoma</keyword>
  <keyword>recurrent childhood gemistocytic astrocytoma</keyword>
  <keyword>recurrent childhood oligoastrocytoma</keyword>
  <keyword>recurrent childhood pilocytic astrocytoma</keyword>
  <keyword>recurrent childhood pilomyxoid astrocytoma</keyword>
  <keyword>recurrent childhood pleomorphic xanthoastrocytoma</keyword>
  <keyword>recurrent childhood protoplasmic astrocytoma</keyword>
  <keyword>untreated childhood cerebellar astrocytoma</keyword>
  <keyword>untreated childhood cerebral astrocytoma</keyword>
  <keyword>untreated childhood diffuse astrocytoma</keyword>
  <keyword>untreated childhood fibrillary astrocytoma</keyword>
  <keyword>untreated childhood gemistocytic astrocytoma</keyword>
  <keyword>untreated childhood oligoastrocytoma</keyword>
  <keyword>untreated childhood pilocytic astrocytoma</keyword>
  <keyword>untreated childhood pilomyxoid astrocytoma</keyword>
  <keyword>untreated childhood pleomorphic xanthoastrocytoma</keyword>
  <keyword>untreated childhood protoplasmic astrocytoma</keyword>
  <keyword>recurrent childhood gliomatosis cerebri</keyword>
  <keyword>recurrent childhood oligodendroglioma</keyword>
  <keyword>recurrent childhood visual pathway</keyword>
  <keyword>hypothalamic glioma</keyword>
  <keyword>recurrent childhood visual pathway glioma</keyword>
  <keyword>untreated childhood gliomatosis cerebri</keyword>
  <keyword>untreated childhood oligodendroglioma</keyword>
  <keyword>untreated childhood visual pathway</keyword>
  <keyword>untreated childhood visual pathway glioma</keyword>
  <keyword>recurrent childhood giant cell glioblastoma</keyword>
  <keyword>recurrent childhood glioblastoma</keyword>
  <keyword>untreated childhood giant cell glioblastoma</keyword>
  <keyword>untreated childhood glioblastoma</keyword>
  <keyword>childhood choroid plexus tumor</keyword>
  <keyword>childhood grade I meningioma</keyword>
  <keyword>childhood grade II meningioma</keyword>
  <keyword>childhood grade III meningioma</keyword>
  <keyword>minimally differentiated myeloid leukemia (M0)</keyword>
  <keyword>myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>childhood acute myelomonocytic leukemia (M4)</keyword>
  <keyword>childhood acute promyelocytic leukemia (M3)</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>untreated childhood acute myeloid leukemia</keyword>
  <keyword>other myeloid malignancies</keyword>
  <keyword>childhood acute monoblastic leukemia (M5a)</keyword>
  <keyword>childhood acute monocytic leukemia (M5b)</keyword>
  <keyword>childhood acute erythroleukemia (M6)</keyword>
  <keyword>childhood acute megakaryocytic leukemia (M7)</keyword>
  <keyword>unspecified childhood solid tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyproheptadine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm I Cyproheptadine Hydrochloride</title>
          <description>Patients receive oral cyproheptadine hydrochloride twice daily for 8 weeks.
cyproheptadine hydrochloride: Given orally</description>
        </group>
        <group group_id="P2">
          <title>Arm II Placebo</title>
          <description>Patients receive an oral placebo twice daily for 8 weeks.
placebo: Given orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I Cyproheptadine Hydrochloride</title>
          <description>Patients receive oral cyproheptadine hydrochloride twice daily for 8 weeks.
cyproheptadine hydrochloride: Given orally</description>
        </group>
        <group group_id="B2">
          <title>Arm II Placebo</title>
          <description>Patients receive an oral placebo twice daily for 8 weeks.
placebo: Given orally</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.2" spread="5.7"/>
                    <measurement group_id="B2" value="12.0" spread="4.7"/>
                    <measurement group_id="B3" value="11.2" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participant With Weight Loss ≥ 5% at the 8- Week Assessment When Compared to Baseline</title>
        <time_frame>8 weeks</time_frame>
        <population>LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I Cyproheptadine Hydrochloride</title>
            <description>Patients receive oral cyproheptadine hydrochloride twice daily for 8 weeks.
cyproheptadine hydrochloride: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Arm II Placebo</title>
            <description>Patients receive an oral placebo twice daily for 8 weeks.
placebo: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Participant With Weight Loss ≥ 5% at the 8- Week Assessment When Compared to Baseline</title>
          <population>LOCF</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Severity of Weight Loss</title>
        <description>Change from Baseline in Weight Z score</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>Completers =</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I Cyproheptadine Hydrochloride</title>
            <description>Patients receive oral cyproheptadine hydrochloride twice daily for 8 weeks.
cyproheptadine hydrochloride: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Arm II Placebo</title>
            <description>Patients receive an oral placebo twice daily for 8 weeks.
placebo: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Weight Loss</title>
          <description>Change from Baseline in Weight Z score</description>
          <population>Completers =</population>
          <units>Z score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="1.15"/>
                    <measurement group_id="O2" value="-0.02" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pattern of Weight in the Study Population</title>
        <description>Change from Baseline in Weight</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>Completers</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I Cyproheptadine Hydrochloride</title>
            <description>Patients receive oral cyproheptadine hydrochloride twice daily for 8 weeks.
cyproheptadine hydrochloride: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Arm II Placebo</title>
            <description>Patients receive an oral placebo twice daily for 8 weeks.
placebo: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Pattern of Weight in the Study Population</title>
          <description>Change from Baseline in Weight</description>
          <population>Completers</population>
          <units>Kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.79"/>
                    <measurement group_id="O2" value="-0.32" spread="3.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm I Cyproheptadine Hydrochloride</title>
          <description>Patients receive oral cyproheptadine hydrochloride twice daily for 8 weeks.
cyproheptadine hydrochloride: Given orally</description>
        </group>
        <group group_id="E2">
          <title>Arm II Placebo</title>
          <description>Patients receive an oral placebo twice daily for 8 weeks.
placebo: Given orally</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decrease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Neutrophil count decrease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Intracranial hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and Subcutaneous tissue disorders other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Angelina Fink, Research Base Administrator</name_or_title>
      <organization>SunCoast CCOP Research Base at the University of South Florida</organization>
      <phone>813-396-9245</phone>
      <email>angelina.fink@epi.usf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

